Expert Comment: Caspian Trial Of Durvalumab In Sclc | Raffaele Califano

Expert comment: CASPIAN trial of durvalumab in SCLC | Raffaele Califano

Medicine Matters oncology

Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC

CASPIAN Trial: Durvalumab and Chemotherapy in ES-SCLC

Chemoimmunotherapy for ES SCLC: CASPIAN Trial

Durvalumab following chemoradiotherapy improves survival in patients with limited-stage small-ce...

Stage III NSCLC: When to Start Durvalumab

Extensive-Stage SCLC: Potential in the CASPIAN Trial

Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials

Frontline I-O Strategies in SCLC: Practical Implications

HUDSON: Durvalumab combination therapies to overcome PD-L1 blockade resistance in advanced NSCLC

Results From the CASPIAN Trial in SCLC

Durvalumab after CT RT in Limited Stage SCLC Journal Club

TMH MedOnco Varanasi

Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives

PeerView Oncology

Extending durvalumab maintenance to special populations

Discussion of IMpower133 and CASPIAN Trials

Targeted Oncology

The CASPIAN Trial in Extensive-Stage SCLC

Treating for Stage III NSCLC After Progression on Durvalumab

Consolidation Durvalumab Could Be New SOC in Limited-Stage SCLC

Four chemo cycles given with durvalumab ± tremelimumab optimise response in patients with mNSCLC

Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLC